Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: Findings from the international VErapamil-SR/ trandolapril study

Anthony A. Bavry, R. David Anderson, Yan Gong, Scott J. Denardo, Rhonda M. Cooper-Dehoff, Eileen M. Handberg, Carl J. Pepine

Research output: Contribution to journalArticlepeer-review

107 Scopus citations

Abstract

Hypertension is a common risk factor for peripheral arterial disease (PAD). Guidelines suggest treating PAD patients to a blood pressure <130/80 mm Hg; therefore, our objective was to explore whether attainment of this target blood pressure is associated with improved outcomes. We performed a post hoc analysis of the INternational VErapamil-SR/Trandolapril STudy, a randomized clinical trial, which included hypertensive patients with concomitant PAD and coronary artery disease. There were 2699 PAD patients followed for a mean of 2.7 years (60 970 patient-years). The primary outcome, all-cause death, nonfatal myocardial infarction, or nonfatal stroke, occurred in 16.3% of PAD patients versus 9.2% without PAD (adjusted hazard ratio: 1.26 [95% CI: 1.13 to 1.40]; P<0.0001). The primary outcome occurred least frequently among PAD patients treated to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg. PAD patients displayed a J-shape relationship with systolic blood pressure and the primary outcome, although individuals without PAD did not. PAD patients may require a different target blood pressure than those without PAD.

Original languageEnglish (US)
Pages (from-to)48-53
Number of pages6
JournalHypertension
Volume55
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Keywords

  • Blocker
  • Calcium antagonist
  • Coronary artery disease
  • Hypertension prognosis
  • Peripheral arterial disease
  • Peripheral vascular disease

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: Findings from the international VErapamil-SR/ trandolapril study'. Together they form a unique fingerprint.

Cite this